Articles & Research
Educational guides, regulatory updates, safety information, and market analysis. All content is independently researched.
PCAC July 2026 Results: What the FDA Advisory Committee Decided on 7 Peptides
The FDA's Pharmacy Compounding Advisory Committee met July 23-24, 2026 to evaluate 7 peptide compounds for 503A inclusion. Here's what they decided and what it means for patients, clinics, and the compounding industry.
The Biohacker's Guide to Peptide Safety
If you're sourcing peptides from research vendors and self-administering, this guide covers the practical safety protocols you need to minimize risk — from sterile reconstitution technique to recognizing when something has gone wrong.
Compounding Pharmacy Red Flags: How to Spot a Bad Actor
Not all compounding pharmacies are created equal. With the FDA issuing warning letters and the PCAC meeting approaching, here's how to identify legitimate pharmacies — and avoid dangerous ones.
The Economics of Peptide Therapy: Why It Costs What It Costs
Peptide therapy costs range from $50/month to $2,000+. Here's what drives the price — from raw material sourcing to pharmacy markup — and how to evaluate whether you're paying a fair price.
The Complete Guide to Finding a Peptide-Friendly Physician
Finding a physician who understands peptide therapy — and won't dismiss your interest outright — requires knowing where to look, what questions to ask, and which red flags to watch for. This guide covers the full process from search to first appointment.
Peptide Therapy for Women: What the Research Actually Shows
Most peptide research has been conducted on men. Here's what we know — and don't know — about how peptides affect women differently, from hormonal interactions to dosing considerations.
Peptide Therapy Insurance Coverage: What's Covered and What's Not
Navigating insurance coverage for peptide therapy is confusing. This guide breaks down which peptides are covered by insurance, what Medicare's new GLP-1 policy means, why compounded peptides aren't covered, and how to minimize out-of-pocket costs through HSA/FSA, patient assistance programs, and prior authorization strategies.
Understanding Peptide Purity: Why 98% Isn't Always 98%
A '99% pure' peptide from one vendor may not be equivalent to '99% pure' from another. This guide breaks down what purity actually means in analytical chemistry, the hidden factors that affect real-world potency, and how to interpret COA data correctly.
We Analyzed 50 Peptide COAs. Here's What We Found.
We collected and reviewed 50 Certificates of Analysis from research vendors, compounding pharmacies, and international suppliers. The results reveal a troubling gap between claimed and actual quality.
What Is CJC-1295? Mechanism, Uses, Risks, and FDA Status
A comprehensive, evidence-based overview of CJC-1295 — a synthetic growth hormone releasing hormone analog used in research for its potential to stimulate sustained growth hormone secretion.
What Is Dihexa? Mechanism, Uses, Risks, and FDA Status
An evidence-based overview of Dihexa — a potent angiotensin IV analog studied for cognitive enhancement and neuroprotection, with research suggesting it may be millions of times more potent than BDNF at promoting synaptic connectivity.
What Is Epitalon? Mechanism, Uses, Risks, and FDA Status
An evidence-based overview of Epitalon (Epithalon) — a synthetic tetrapeptide studied for its potential to activate telomerase, extend telomere length, and modulate aging-related biomarkers.
What Is KPV? Mechanism, Uses, Risks, and FDA Status
An evidence-based overview of KPV — a naturally derived anti-inflammatory tripeptide from alpha-melanocyte stimulating hormone (alpha-MSH) with research applications in gut inflammation, skin conditions, and immune modulation.
What Is LL-37? Mechanism, Uses, Risks, and FDA Status
An evidence-based overview of LL-37 (Cathelicidin) — the only human cathelicidin antimicrobial peptide, with broad-spectrum antimicrobial activity and immunomodulatory properties relevant to infection, wound healing, and immune defense.
What Is MOTS-c? Mechanism, Uses, Risks, and FDA Status
An evidence-based overview of MOTS-c — a mitochondrial-derived peptide involved in metabolic regulation, exercise mimicry, and cellular energy homeostasis, with emerging research in aging and metabolic disease.
What Is PT-141? Mechanism, Uses, Risks, and FDA Status
An evidence-based overview of PT-141 (Bremelanotide) — a melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder in women, with ongoing research into broader sexual dysfunction applications.
What Is Retatrutide? Mechanism, Uses, Risks, and FDA Status
An evidence-based overview of Retatrutide — a novel triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously, showing unprecedented weight loss results in Phase II clinical trials.
What Is Selank? Mechanism, Uses, Risks, and FDA Status
An evidence-based overview of Selank — a synthetic anxiolytic peptide derived from the immunomodulatory peptide tuftsin, developed in Russia as a nootropic with anti-anxiety and cognitive-enhancing properties.
What Is Tesamorelin? Mechanism, Uses, Risks, and FDA Status
An evidence-based overview of Tesamorelin — an FDA-approved synthetic growth hormone releasing hormone (GHRH) analog used to reduce visceral adiposity in HIV-associated lipodystrophy, with emerging research in cognitive function and liver fat reduction.
What Happens If the FDA Reverses Course on Peptides
The PCAC could vote no. The next administration could reverse the current one's position. Here's what a regulatory reversal would actually mean for patients, clinics, and the compounding industry.
What Is AOD-9604? Uses, Risks, and FDA Status
A clear, evidence-based overview of AOD-9604 — what it is, how it works, what it's used for, known risks, and current FDA regulatory status.
What Is BPC-157? Uses, Risks, and FDA Status
A clear, evidence-based overview of BPC-157 — what it is, how it works, what it's used for, known risks, and current FDA regulatory status.
What Is GHK-Cu? Uses, Risks, and FDA Status
A clear, evidence-based overview of GHK-Cu — what it is, how it works, what it's used for, known risks, and current FDA regulatory status.
What Is Ipamorelin? Uses, Risks, and FDA Status
A clear, evidence-based overview of ipamorelin — what it is, how it works, what it's used for, known risks, and current FDA regulatory status.
What Is Semaglutide? Uses, Risks, and FDA Status
A clear, evidence-based overview of semaglutide — what it is, how it works, what it's used for, known risks, and current FDA regulatory status.
What Is Semax? Uses, Risks, and FDA Status
A clear, evidence-based overview of Semax — what it is, how it works, what it's used for, known risks, and current FDA regulatory status.
What Is Sermorelin? Uses, Risks, and FDA Status
A clear, evidence-based overview of sermorelin — what it is, how it works, what it's used for, known risks, and current FDA regulatory status.
What Is TB-500? Uses, Risks, and FDA Status
A clear, evidence-based overview of TB-500 — what it is, how it works, what it's used for, known risks, and current FDA regulatory status.
What Is Thymosin Alpha-1? Uses, Risks, and FDA Status
A clear, evidence-based overview of Thymosin Alpha-1 — what it is, how it works, what it's used for, known risks, and current FDA regulatory status.
What Is Tirzepatide? Uses, Risks, and FDA Status
A clear, evidence-based overview of tirzepatide — what it is, how it works, what it's used for, known risks, and current FDA regulatory status.
What Hims & Hers Entering Peptides Means for the Market
Hims & Hers acquired a peptide manufacturing facility, their stock surged 48%, and they're building a peptide product line. Here's what this means for patients, clinics, and the competitive landscape.
How to Submit a Public Comment to the FDA Before July 9 (Step-by-Step)
The FDA's public comment period for the July 2026 PCAC meeting closes July 9. Here's exactly how to submit a comment on docket FDA-2025-N-6895 — and what to say if you're a patient, clinician, or researcher.
The Complete Guide to Peptide Reconstitution
How to properly reconstitute lyophilized peptides: bacteriostatic water ratios, syringe math, storage requirements, and the mistakes that ruin potency.
What Category 2 Removal Actually Means (And What It Doesn't)
The FDA removed 12 peptides from Category 2 in April 2026. Many people think this means they're legal to compound. It doesn't. Here's the critical legal nuance that most sources are getting wrong.
503A vs 503B: What's the Difference Between Compounding Pharmacies?
The terms 503A and 503B come up constantly in peptide therapy discussions, but most patients have no idea what they mean. Here's a clear breakdown of the two types of compounding pharmacies, how they're regulated, and why it matters for your peptide prescription.
Why Your Peptide COA Might Be Fake (And How to Tell)
Not all Certificates of Analysis are created equal. Some are outright fabricated. Here's how to spot the red flags, verify authenticity, and protect yourself from low-quality or counterfeit peptides.
MOTS-c: The Mitochondrial Peptide That Might Change Metabolic Medicine
MOTS-c is a mitochondria-derived peptide that regulates metabolism, improves insulin sensitivity, and may protect against age-related metabolic decline. It's also heading to the FDA's PCAC meeting in July 2026. Here's what the science says.
What Does Peptide Therapy Actually Cost in 2026?
Peptide therapy pricing is opaque. We compiled real pricing data from 7 telehealth clinics to show what you'll actually pay — from consultation fees to monthly compound costs.
Semax: The Russian Nootropic Peptide Now Under FDA Review
Semax has been used clinically in Russia for decades to treat stroke and cognitive impairment. Now it's one of seven peptides heading to the FDA's PCAC meeting in July 2026. Here's what the research says, what the regulatory path looks like, and what it means for US access.
The History of Peptide Regulation: From the 2023 Ban to the 2026 Reversal
How 19 peptides went from legally compoundable to banned to partially restored in three years — a timeline of the most turbulent period in peptide regulatory history.
What Is Pharmaceutical-Grade? Understanding Peptide Quality Standards
The term 'pharmaceutical-grade' gets thrown around constantly in the peptide space. Here's what it actually means, how it differs from research-grade, and why it matters for safety.
Semaglutide vs Tirzepatide vs Retatrutide: A Data-Driven Comparison
Three generations of incretin-based therapy — one approved in 2017, one in 2022, one still in trials. Here's how they compare on efficacy, mechanism, side effects, and what the data actually shows.
BPC-157 vs KPV: Two Healing Peptides, Different Strengths
BPC-157 and KPV are both anti-inflammatory healing peptides currently under FDA review. They work through different mechanisms and suit different conditions. Here's how to understand the difference.
How to Find a Legitimate Peptide Clinic: A Practical Guide
With peptide therapy expanding rapidly in 2026, the number of providers has grown — but so has the variation in quality. Here's exactly what to look for, what to ask, and what to avoid.
Peptide Stacking: What It Is, What the Research Says, and What to Know Before You Start
Peptide stacking — combining multiple compounds in a single protocol — is one of the most searched topics in the peptide space and one of the least well-covered. Here's an honest breakdown of the rationale, the evidence, the risks, and how to think about it.
The July 2026 PCAC Meeting: What's at Stake for BPC-157, TB-500, Semax, and More
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee will decide whether seven peptides — including BPC-157 and TB-500 — get formally authorized for compounding. Here's what the process looks like, what outcomes are possible, and what it means for patients and clinicians.
FDA Removes 12 Peptides from Category 2: What It Actually Means
On April 15, 2026, the FDA announced that 12 peptides — including BPC-157, TB-500, Semax, and Epitalon — will exit the Category 2 restricted list on April 22. Here's a clear breakdown of what changed, what didn't, and what happens next.
The 2026 FDA Peptide Reclassification: What Changed and What It Means
In February 2026, 14 peptides were reclassified from Category 2 to Category 1. Here's what that means for patients, clinics, and the peptide market.
How to Read a Certificate of Analysis (COA) for Peptides
A COA is the single most important document for verifying peptide quality. Here's how to read one, what to look for, and how to spot fakes.
Peptide Safety Guide: What You Need to Know Before Starting
Considering peptide therapy? Here's a practical safety guide covering sourcing, administration, side effects, and when to seek medical attention.
What Is BPC-157? A Complete Guide to the Body Protection Compound
BPC-157 is one of the most talked-about peptides in the biohacking and recovery space. Here's what the research actually says about this gastric peptide — mechanism, uses, risks, and current legal status.